دورية أكاديمية
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.
| العنوان: | Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients. |
|---|---|
| المؤلفون: | Aksamit TR; COPD Foundation, Washington, District of Columbia.; Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota., Locantore N; COPD Foundation, Washington, District of Columbia., Addrizzo-Harris D; School of Medicine, New York University, New York, New York., Ali J; Health Sciences Center, Louisiana State University, New Orleans, Louisiana., Barker A; Division of Pulmonary and Critical Care, School of Medicine, Oregon Health and Science University, Portland, Oregon., Basavaraj A; School of Medicine, New York University, New York, New York., Behrman M; University of Kansas Medical Center, University of Kansas, Kansas City, Kansas., Brunton AE; COPD Foundation, Washington, District of Columbia., Chalmers S; Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota., Choate R; COPD Foundation, Washington, District of Columbia.; Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, Kentucky., Dean NC; Schmidt Chest Clinic, Intermountain Medical Center, Murray, Utah., DiMango A; Center for Chest Disease, College of Physicians and Surgeons, Columbia University, New York, New York., Fraulino D; Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of Connecticut, Farmington, Connecticut., Johnson MM; Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, Florida., Lapinel NC; Section of Pulmonary, Critical Care Medicine, Department of Medicine, Northwell Health, New Hyde Park, New York., Maselli DJ; San Antonio Veterans Administration, San Antonio, Texas., McShane PJ; Health Science Center, University of Texas at Tyler, Tyler, Texas., Metersky ML; Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of Connecticut, Farmington, Connecticut., Miller BE; COPD Foundation, Washington, District of Columbia., Naureckas ET; Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, Illinois., O'Donnell AE; Georgetown University Medical Center, Georgetown University, Washington, District of Columbia., Olivier KN; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Prusinowski E; Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, Illinois., Restrepo MI; San Antonio Veterans Administration, San Antonio, Texas., Richards CJ; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts., Rhyne G; Department of Infectious Disease, Oregon Health and Science University - Portland State University School of Public Health, Oregon Health and Science University School of Medicine, Portland, Oregon; and., Schmid A; University of Kansas Medical Center, University of Kansas, Kansas City, Kansas., Solomon GM; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Tal-Singer R; COPD Foundation, Washington, District of Columbia., Thomashow B; Center for Chest Disease, College of Physicians and Surgeons, Columbia University, New York, New York., Tino G; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Tsui K; Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, Illinois., Varghese SA; Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of Connecticut, Farmington, Connecticut., Warren HE; Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, University of Connecticut, Farmington, Connecticut., Winthrop K; Department of Infectious Disease, Oregon Health and Science University - Portland State University School of Public Health, Oregon Health and Science University School of Medicine, Portland, Oregon; and., Zha BS; University of California, San Francisco, San Francisco, California. |
| المصدر: | American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 Jul 01; Vol. 210 (1), pp. 108-118. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Thoracic Society Country of Publication: United States NLM ID: 9421642 Publication Model: Print Cited Medium: Internet ISSN: 1535-4970 (Electronic) Linking ISSN: 1073449X NLM ISO Abbreviation: Am J Respir Crit Care Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2000- : New York, NY : American Thoracic Society Original Publication: New York, NY : American Lung Association, c1994- |
| مواضيع طبية MeSH: | Bronchiectasis*/mortality , Bronchiectasis*/physiopathology , Bronchiectasis*/epidemiology , Registries* , Mycobacterium Infections, Nontuberculous*/mortality , Mycobacterium Infections, Nontuberculous*/epidemiology, Humans ; Male ; Female ; Middle Aged ; Aged ; United States/epidemiology ; Hospitalization/statistics & numerical data ; Proportional Hazards Models ; Nontuberculous Mycobacteria ; Disease Progression |
| مستخلص: | Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives: To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods: Patients in the Bronchiectasis and NTM Research Registry with ⩾5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log-rank test. Measurements and Main Results: In total, 2,634 patients were included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV |
| التعليقات: | Comment in: Am J Respir Crit Care Med. 2024 Jul 1;210(1):18-20. doi: 10.1164/rccm.202405-0936ED. (PMID: 38747644) |
| معلومات مُعتمدة: | United States Richard H. Scarborough Bronchiectasis Research Fund; United States Anna-Maria and Stephen Kellen Foundation; United States Bronchiectasis and NTM Industry Advisory Committee |
| فهرسة مساهمة: | Keywords: Pseudomonas aeruginosa; exacerbation; hospitalization; mortality; spirometry |
| تواريخ الأحداث: | Date Created: 20240426 Date Completed: 20240701 Latest Revision: 20240701 |
| رمز التحديث: | 20240701 |
| DOI: | 10.1164/rccm.202307-1165OC |
| PMID: | 38668710 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-4970 |
|---|---|
| DOI: | 10.1164/rccm.202307-1165OC |